After grabbing 14.29 million shares, the institutional investor is now in possession of 14.29 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 11.37% having worth around $19.57 million. Moreover, Senvest Management LLC increased its share by 8.03 million to have a control over 10.74 million shares. And Balyasny Asset Management LP raised its holdings to 3.76 million shares by acquiring 3.77 million shares or 3.00% of the stake.
LumiraDx Limited (LMDX) concluded trading on 01/11/23 at a closing price of $0.90, with 0.43 million shares of worth about $0.39 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -63.41% during that period and on Wednesday the price saw a gain of about 1.83%. Currently the company’s common shares owned by public are about 304.41M shares, out of which, 36.95M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 5 analysts are covering the LMDX stock and their offered price forecasts bring an average price target of $3.49. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $7.75 and could fall to a lowest price of $1.20. The stock’s current price level is 74.21% above of average price target set by the analysts, while a rise to estimated low would result in gain of 25.0% for the stock. However, touching the estimated high of $7.75 would mean a gain of 88.39% for the stock.
LumiraDx Limited (NASDAQ: LMDX) started trading at $0.91, above $0.03 from concluding price of the previous day. However, the stock later moved at a day high price of 0.9500, or with a gain of 1.83%. Stock saw a price change of 0.35% in past 5 days and over the past one month there was a price change of -15.09%. Year-to-date (YTD), LMDX shares are showing a performance of 0.00% which decreased to -89.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.77 but also hit the highest price of $10.00 during that period. The average intraday trading volume for LumiraDx Limited shares is 281.46K. The stock is currently trading -2.07% below its 20-day simple moving average (SMA20), while that difference is down -15.80% for SMA50 and it goes to -60.79% lower than SMA200.
Bill & Melinda Gates Foundation T acquired 14.29 million shares of LumiraDx Limited having value of about $19.57 million. LumiraDx Limited (NASDAQ: LMDX) currently have 304.41M outstanding shares and institutions hold larger chunk of about 26.70% of that. Holding of mutual funds in the company is about 0.02% while other institutional holders and individual stake holders have control over 28.36% and — of the stake respectively.
The stock has a current market capitalization of $150.20M. It has posted earnings per share of -$1.23 in the same period. It has Quick Ratio of 1.60 while making debt-to-equity ratio of 21.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LMDX, volatility over the week remained 7.26% while standing at 11.18% over the month.
Analysts are in expectations that LumiraDx Limited (LMDX) stock would likely to be making an EPS of -$0.26 in the current quarter, while forecast for next quarter EPS is -$0.2 and it is -$0.65 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.3 which is -$0.24 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.46 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 33.00% while it is estimated to increase by 55.30% in next year.
Analysts at 5 brokerage firms have issued recommendations for the LumiraDx Limited (LMDX)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.80. Out of those 5 Wall Street analysts, 3 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on November 15, 2021 offering an Outperform rating for the stock and assigned a target price of $20 to it. Coverage by BTIG Research stated LumiraDx Limited (LMDX) stock as a Buy in their note to investors on October 27, 2021, suggesting a price target of $12 for the stock.